Producing CAR T cell therapy at a lower cost
Chimeric antigen receptor (CAR) T cell therapy is a new and in some cases highly effective form of immunotherapy to treat certain types of cancer of the blood and lymph system. This promising treatment comes at a cost.
EHA-Patient Joint Policy Symposium at EHA24
Delivering on the Promise: Innovative Therapies and the Quest for (Real) Patient Benefit.
EHA Guidance Document: The Process of CAR T-Cell Therapy in Europe
This document has been created to provide practical guidance for centers and national authorities in Europe that are interested in introducing chimeric antigen receptor (CAR)-T cell therapy.